DATE

September 16-17, 2017

LOCATION

Hyatt Regency Huntington Beach
21500 Pacific Coast Hwy, Huntington Beach, CA 92648 • (714) 698-1234

Hotel Info

COURSE DIRECTORS

IAN CARROLL, PhD
Assistant Professor,Department of Medicine
Division of Gastroenterology and Hepatology
UNC Chapel Hill
Chapel Hill, NC

MARK PIMENTEL,MD, FRCP(C)
Director, GI Motility Program
Director, GI Motility Laboratory
Cedars-Sinai Medical CenterLos Angeles, CA

OVERVIEW

The 1.5-day Gut Microbiome Conference has been conceived to immerse both clinicians and researchers in a comprehensive educational experience, designed to explore how the human microbiome and how altered microbial balance may contribute to chronic disorders such as diabetes/metabolic syndrome, gastrointestinal disorders (IBS, IBD, fatty liver disease), obesity, cancer, and even neurological conditions.

FACULTY/AGENDA

GOAL STATEMENT

To convene a group of researchers, physicians, and other health care professionals with a shared interest in the clinical importance and relevance of modulating the gut microbiome to revolutionize the management of infectious and chronic disease states in which human intestinal microbiota play a critical role. Through the extensive information presented on the pathophysiologic mechanisms of intestinal microbiota, novel detection modalities to assist accurate and timely diagnosis, and therapeutic approaches to manipulating and correcting dysbiosis, participants in the 1.5- day Gut Microbiome Conference will review the most current information emerging from a critical and burgeoning field of research and clinical development.

TARGET AUDIENCE

Gastroenterologists; internists; family practitioners; physician assistants, physicians-in-training and researchers with an interest in the pathophysiology, diagnosis, and clinical management of gastrointestinal and other common diseases and their relationship to the microbiome.

STATEMENT OF NEED/PROGRAM OVERVIEW

Mounting evidence suggests an active and complex involvement of the intestinal microbiota in common chronic disorders such as diabetes/metabolic syndrome, gastrointestinal disorders (IBS, IBD, fatty liver disease), obesity, cancer, and even neurological conditions. It is also increasingly clear that influencing the gut microbiome has the potential to revolutionize the management of not only infectious diseases, but a broad range of other conditions. Thus, clinicians would benefit from a better appreciation of how microbial-induced inflammation and immunological reactivity may assist in identifying origins of disease, classifying patient subgroups, and individualizing effective treatment strategies.

CME LEARNING OBJECTIVES

Upon completion of this conference, participants should be better able to:

  • Discuss evolving concepts and current research advances regarding the role of the gut microbiome in GI health and disease
  • Explain the pathophysiologic influence of dysbiosis and microbial metabolism as it relates to the etiology and progression of common diseases, including diabetes, fatty liver disease, cancer, obesity, and gastrointestinal diseases
  • Discuss how modification of the gut microbiome is becoming a therapeutic strategy in common GI diseases such as IBS, IBD, and C. difficile infection
  • Discuss how changes in the diet effect the gut microbiota and its impact on health and human disease
  • Explain the impact of probiotics on the gut microbiome and their use in managing functional gastrointestinal disorders
  • Discuss the current advances in testing and serum markers for the Microbiome
  • CREDIT DESIGNATION

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of the Rehoboth McKinley Christian Health Care Services (RMCHCS) and Focus Medical Communications. RMCHCS is accredited by NMMS to provide continuing medical education for physicians.

    RMCHCS designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

    Jointly provided by the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS) and Focus Medical Communications.

    This activity is supported by an educational grant from Salix Pharmaceuticals, Inc. A Division of Valeant LLC.